Clinical trials: Tick-borne Encephalitis
Tick-borne Encephalitis
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age…
- Trial name
- NCT00161863
- Testing
- FSME-IMMUN NEW 0.25 ml
- Where
- 8 sites in Austria, Germany and 1 more
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis (TBE)
TBE Seropersistence up to 10 Years After First Booster in Adults
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
- Trial name
- NCT01582698
- Testing
- FSME-IMMUN 0.5 ml
- Where
- 2 sites in Poland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
The purpose of this study is to assess: TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA (IMMUNOZYM FSME IgG)…
- Trial name
- NCT00503529
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 2 sites in Poland
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Pfizer